Tetrabenazine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1843 publications
Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study.
Journal: Journal of Huntington's disease
Published: August 14, 2026
Vesicular Monoamine Transporters at the Crossroads of Structure and Function: Advances, Challenges, and Future Perspectives.
Journal: Annual review of pharmacology and toxicology
Published: August 07, 2026
Perceptions on the diagnosis and treatment of patients with tardive dyskinesia: a cross-sectional survey among physicians in Italy.
Journal: Rivista di psichiatria
Published: July 21, 2026
Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis.
Journal: Biological & pharmaceutical bulletin
Published: June 21, 2026
Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal: Psychopharmacology bulletin
Published: June 10, 2026
Management of severe tardive dyskinesia induced by arpiprazole in a schizophrenic patient: a case report.
Journal: Journal of medical case reports
Published: May 31, 2026
Acute Onset Extrapyramidal Symptoms With Clozapine: A Report of a Rare Case.
Journal: Cureus
Published: May 11, 2026
Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.
Journal: Psychiatry and clinical neurosciences
Published: May 09, 2026
Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.
Journal: The Journal of clinical psychiatry
Published: May 07, 2026
Deciphering the interaction of tetrabenazine with lactoferrin: Insights from molecular dynamics and multi-spectroscopic approaches.
Journal: International journal of biological macromolecules
Published: May 06, 2026
L-theanine from Camellia sinensis (L.) attenuates 3-NP-induced Huntington's disease-like alterations by remedying behavioral patterns and modulating neurotransmitters across three distinct brain regions: evidence from in-vivo and in-silico approaches.
Journal: Metabolic brain disease
Published: April 18, 2026
Last Updated: 09/26/2026